intranasal insulin human

Nastech's intranasal insulin is a rapid-acting formulation of recombinant human insulin designed for delivery via the nasal mucosa. It utilizes Nastech's proprietary tight junction modulation technology to enhance the permeability of the nasal epithelium, allowing for systemic absorption of the insulin peptide. Developed primarily for the treatment of postprandial glucose excursions in patients with Type 1 and Type 2 diabetes mellitus, the product aimed to provide a non-invasive alternative to subcutaneous injections with a pharmacokinetic profile mimicking the early-phase insulin secretion of a healthy pancreas. Clinical development reached Phase 2, including studies comparing its efficacy to insulin aspart (NovoLog), but development was discontinued after Merck & Co. terminated their collaboration in 2008.

Other names

Nastech nasal insulinNastech intranasal insulin